(Q24202910)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

14 May 2020

1

Nithya Gogtay

Nithya

Gogtay

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

14 May 2020

5

David Sinclair

David

Sinclair

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

14 May 2020

4

Piero L

Olliaro

Piero L Olliaro

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

14 May 2020

Sridharan Kannan

2

Sridharan

Kannan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

Cochrane Database of Systematic Reviews

14 May 2020

language of work or name

English

0 references

publication date

25 October 2013

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

14 May 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

14 May 2020

page(s)

CD008492

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

A trial of combination antimalarial therapies in children from Papua New Guinea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Artemisinin combination therapy for vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Mefloquine in infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Therapeutic responses to different antimalarial drugs in vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Pyronaridine-artesunate versus mefloquine plus artesunate for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

The pathophysiology of vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Prevention and treatment of vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Resistance to therapies for infection by Plasmodium vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Artemisinin Resistance in Plasmodium falciparum Malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Primaquine for preventing relapses in people with Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

A long neglected world malaria map: Plasmodium vivax endemicity in 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Mixed-species malaria infections in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Effects of artemisinin derivatives on malaria transmissibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Artemisinin-based combination therapy for treating uncomplicated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Antimalarial Drug Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Averting a malaria disaster

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

The assessment of antimalarial drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives

21 January 2018

2 references

12 December 2020

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB3

7 January 2021

inferred from DOI database lookup

The neglected burden of Plasmodium vivax malaria

1 reference

12 December 2020

Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua

1 reference

12 December 2020

Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand

1 reference

12 December 2020

Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua

1 reference

12 December 2020

Vivax malaria: neglected and not benign

1 reference

12 December 2020

Artemisinin-based combination treatment of falciparum malaria.

1 reference

12 December 2020

Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India

1 reference

12 December 2020

Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia.

1 reference

12 December 2020

Primaquine resistance in Plasmodium vivax

1 reference

12 December 2020

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.

1 reference

12 December 2020

Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria.

1 reference

12 December 2020

A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria.

1 reference

12 December 2020

10.1002/14651858.CD008492.PUB3

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2643855

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

release_7rh3imfvb5akpjz25vrzoh7ey4

14 May 2020

Fatcat ID

0 references

OpenCitations bibliographic resource ID

2643855

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6532731&resulttype=core&format=json

14 May 2020

PubMed publication ID

24163021

1 reference